Results 131 to 140 of about 85,599,608 (253)

Alogliptin benzoate for management of type 2 diabetes

Vascular Health and Risk Management, 2015
Yoshifumi Saisho Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Abstract: Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress ...
Saisho Y
doaj  

Cost-effectiveness analysis of oral anti-diabetic medications: DPP-4 inhibitor as monotherapy vs. combination therapy in type 2 diabetic patients in Malang, Indonesia [PDF]

Background: Several anti-diabetic medications are covered under the Indonesian Universal Health Coverage (BPJS). However, metformin is typically prioritized over other options, such as DPP-4 inhibitors, because they are considered costly.
Sidek Ahmad, Zulkhairul Naim, Yurina, Valentina, Che Hasan, Muhammad Kamil, Oktaviana, Prita Aldilla, Triastuti, Efta   +4 more
core   +2 more sources

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen   +9 more
wiley   +1 more source

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

, 2009
Type 2 diabetes mellitus (T2DM) is a global epidemic with increasing impact on individuals and healthcare providers. Available treatments (such as metformin, sulfonylureas, glitazones, and insulin) have proven unsatisfactory in producing a long-lasting ...
Piya, Milan K, Piya, Milan, Piya, Milan K. (R19111), Barnett, Anthony, R. Keith Campbell, Barnett, Anthony H., Tahrani, Abd A., Tahrani, Abd; id_orcid, Joshua J. Neumiller, Barnett, Anthony H, Tahrani, Abd A   +10 more
core   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

British Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė, Victor Mathis, Emmanuel Darcq, Aurelijus Burokas, Elena Martín‐García, Rafael Maldonado   +5 more
wiley   +1 more source

Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity

Periodontology 2000, EarlyView., 2023
Abstract Noncommunicable diseases (NCDs) are multifactorial, long‐term, chronic conditions that represent a burden to health‐care systems worldwide as they can only be controlled rather than cured; hence, they require long‐term care. With the exponential increase in NCDs, the occurrence of individuals presenting with more than one chronic disease is ...
Crystal Marruganti, Jean E. Suvan, Francesco D'Aiuto   +2 more
wiley   +1 more source

Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials

, 2018
Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a relatively new class of non-insulin glucose-lowering agents, belonging to the incretin family, which are able to improve glycemic control with a favorable safety profile, since they are associated with a ...
Leporini C., Cernaro V., Russo E., De Sarro G., Rivoli L., Bolignano D., Arturi F., Ursini F., di Paola E. D., Coppolino G., Andreucci M., Rivoli Laura, di Paola, E. D., Cernaro, Valeria, di Paola Eugenio Donato, di Paola, Eugenio Donato, Cernaro Valeria, Andreucci Michele, Christian Leporini, Rivoli, Laura, Ursini, Francesco, De Sarro, Giovambattista, Coppolino, G., Giovambattista De Sarro, Arturi, F., Bolignano, Davide, Russo Emilio, De Sarro, G., Francesco Ursini, Laura Rivoli, Coppolino, Giuseppe, Leporini, Christian, Eugenio Donato di Paola, Leporini, C., Giuseppe Coppolino, Michele Andreucci, Arturi, Franco, Ursini Francesco, Bolignano, D., Andreucci, Michele, Russo, E., Ursini, F., Cernaro, V., Russo, Emilio, Bolignano Davide, Arturi Franco, Franco Arturi, Andreucci, M., Coppolino Giuseppe, De Sarro Giovambattista, Leporini Christian, Davide Bolignano, Emilio Russo, Valeria Cernaro, Rivoli, L.   +54 more
core   +1 more source

Positive modulation of glucagon‐like peptide 1 (GLP‐1) receptor by endogenous haemorphins with implications in glucose metabolism and diabetes

British Journal of Pharmacology, EarlyView.
Haemorphins act on GLP‐1 receptor (GLP‐1R) activity and signalling in a positive allosteric manner. This leads to potentiated GLP‐1‐mediated activity and signalling, as well as insulin synthesis, which may have implications for glucose metabolism and, thereby, diabetes and obesity. (The graph was created in BioRender.com).
Farheen Badrealam Khan, Rwdah Mohamed Alameri, Yasir S. Raouf, Damien Maurel, Naiem Ahmad Wani, Anatoliy Shmygol, Irfa Anwar, Heng B. See, Elizabeth K. M. Johnstone, Elodie Dupuis, Eric Trinquet, Kevin D. G. Pfleger, Emilia Oueis, Mohammed Akli Ayoub   +13 more
wiley   +1 more source

The E‐cadherin‐Wnt‐mir‐994 Axis Repurposes a Cadherin Switch for Niche Robustness and Germline Stem Cell Maintenance

Cell Proliferation, EarlyView.
In the Drosophila ovarian niche, an E‐cadherin‐to‐N‐cadherin switch, mediated by Wnt‐mir‐994 signalling, is repurposed to ensure niche resilience. This compensatory mechanism maintains niche integrity and stem cell support upon E‐cadherin loss, revealing a robustness circuit.
Renjun Tu, Hiu Laam Yau, Runzhi Deng, Sarah E. Webb, Shiyuan Chen, Jianquan Ni, Ting Xie   +6 more
wiley   +1 more source

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice. [PDF]

Biomedicines, 2023
Alshamrani AA, Al-Hamamah MA, Albekairi NA, Attia MSM, Ahmad SF, Assiri MA, Ansari MA, Nadeem A, Bakheet SA, Alanazi WA, Attia SM.   +10 more
europepmc   +1 more source